Commentary: H. pylori eradication therapy after subtotal gastrectomy for gastric cancer - can the qualitative be quantified?
Miraca Life Sciences Research Institute, Miraca Life Sciences, Irving, TX, USA; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA. robert.genta@utsouthwestern.edu.
R M
RM
Genta
D000230:Adenocarcinoma / Q000601:surgery*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D007422:Intestines / Q000473:pathology*; D008297:Male; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D013270:Stomach / Q000473:pathology*; D013274:Stomach Neoplasms / Q000601:surgery*
D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors